(Q87275646)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24519322%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24519322%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Sadahisa Ogasawara

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24519322%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Tetsuhiro Chiba

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24519322%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Yoshihiko Ooka

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24519322%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Naoya Kanogawa

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24519322%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Tenyu Motoyama

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24519322%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Eiichiro Suzuki

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24519322%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Akinobu Tawada

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24519322%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Osamu Yokosuka

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24519322%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

13 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24519322%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Clinical Oncology

7 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24519322%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24519322%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24519322%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

1029-1036

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24519322%20AND%20SRC:MED&resulttype=core&format=json

Management of hepatocellular carcinoma: An update

7 March 2020

cites work

1 reference

12 December 2020

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

12 December 2020

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

1 reference

12 December 2020

Imatinib plasma levels: correlation with clinical benefit in GIST patients

1 reference

12 December 2020

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

1 reference

12 December 2020

Sorafenib in advanced hepatocellular carcinoma

1 reference

12 December 2020

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

Stop and go: yes or no?

1 reference

12 December 2020

Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

12 December 2020

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Sorafenib exposure decreases over time in patients with hepatocellular carcinoma

1 reference

12 December 2020

Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors

1 reference

12 December 2020

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

1 reference

12 December 2020

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

1 reference

12 December 2020

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

1 reference

12 December 2020

10.1007/S10147-014-0668-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24519322%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference